Circulating microRNAs as potential biomarkers for monitoring the response to in vivo treatment with Rituximab in systemic lupus erythematosus patients

Autoimmun Rev. 2020 Apr;19(4):102488. doi: 10.1016/j.autrev.2020.102488. Epub 2020 Feb 13.

¹ Center of Research of Immuno-pathology and Rare Diseases- Coordinating Center of Piemonte and Valle d'Aosta Network for Rare Diseases, Department of Clinical and Biological Sciences, and SCDU Nephrology and Dialysis, University of Turin and S. Giovanni BoscoHospital, Turin, Italy.
² Rheumatology service, IMIBIC/Reina SofiaHospital/University of Cordoba, Cordoba, Spain.
³ Center of Research of Immuno-pathology and Rare Diseases- Coordinating Center of Piemonte and Valle d'Aosta Network for Rare Diseases, Department of Clinical and Biological Sciences, and SCDU Nephrology and Dialysis, University of Turin and S. Giovanni BoscoHospital, Turin, Italy. Electronic address: savino.sciascia@unito.it.

No abstract available

Keywords: Biomarker; Rituximab; SLE; Systemic lupus erythematosus; microRNAs.

Publication types